NEW YORK, January 31, 2017 /PRNewswire/ --
This morning, Stock-Callers.com puts focus on select equities to see howthey have fared over the last few trading sessions: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Tesaro Inc. (NASDAQ: TSRO), Sangamo Therapeutics Inc. (NASDAQ: SGMO), and Cerus Corp. (NASDAQ: CERS). According to a research report by Grand View Research,
At the close on Monday, shares in South San Francisco, California headquartered Portola Pharmaceuticals Inc. saw a slight drop of 0.12%, ending the day at $25.54. The stock recorded a trading volume of 719,023 shares. The Company's shares have advanced 11.38% in the last one month, 27.64% in the previous three months, and 13.81% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 19.38% and 12.13%, respectively. Moreover, shares of Portola Pharma, which develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation, have a Relative Strength Index (RSI) of 62.51.
On December 23rd, 2016, Portola Pharmaceuticals announced that the US Food and Drug Administration (FDA) accepted Portola's New Drug Application (NDA) granting priority review for betrixaban, an oral, once-daily Factor Xa inhibitor anticoagulant, for extended-duration prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for VTE. A priority review shortens the FDA review timeline to 6 months from the standard review period of 10 months.
On January 03rd, 2017, research firm Citigroup upgraded the Company's stock rating from 'Neutral' to 'Buy'. The free research report on PTLA is available at:
Shares in Waltham, Massachusetts headquartered Tesaro Inc. ended the day 0.27% lower at $153.44. A total volume of 1.03 million shares was traded, which was above their three months average volume of 987,870 shares. The stock has gained 13.78% in the past month, 29.87% over the previous three months, and 14.10% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 10.98% and 61.49%, respectively. Furthermore, shares of Tesaro, which identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the US and internationally, have an RSI of 59.89.
On January 13th, 2017, research firm Morgan Stanley initiated an 'Overweight' rating on the Company's stock.
On January 17th, 2017, Tesaro announced the opening of an expanded access program (EAP) in the US for the investigational PARP inhibitor, niraparib. Through this program, niraparib is being made available for eligible women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer following a complete or partial response to platinum-based chemotherapy. An EAP for niraparib in Europe is planned to open in the first half of 2017, and will be initiated on a country-by-country basis. The complimentary report on TSRO can be downloaded at:
On Monday, shares in Richmond, California headquartered Sangamo Therapeutics Inc. finished flat at $3.55 with a total trading volume of 349,187 shares. The stock has advanced 22.41% in the last one month and 16.39% on an YTD basis. The Company's shares are trading above their 50-day moving average by 2.48%. Additionally, shares of Sangamo Therapeutics, which focuses on the research, development, and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation, have an RSI of 49.64.
On January 11th, 2017, Sangamo Therapeutics announced that the US FDA has granted orphan drug designation to SB-318, a genome editing product candidate for the treatment of Mucopolysaccharidosis Type I (MPS I), a rare lysosomal storage disorder. Orphan drug designations are granted to drugs and biologics intended to treat rare diseases. The designation provides incentives to advance development of rare disease drugs and for commercialization of those drugs that progress to approval. Visit us today and download our complete research report on SGMO for free at:
Concord, California headquartered Cerus Corp.'s shares recorded a trading volume of 682,662 shares at the end of yesterday's session. The stock closed the day 3.29% lower at $4.12. The Company's shares are trading below their 50-day moving average by 14.10%. Additionally, shares of Cerus, which focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety, have an RSI of 39.46.
On January 03rd, 2017, Cerus announced that the compensation committee of its board of directors granted fifteen new non-executive employees options to purchase an aggregate of 174,500 shares of the Company's common stock with a per share exercise price of $4.33. Get free access to your technical report on CERS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!